Fig. 2. Comparison of cumulative poor outcome-free survival rates. Patients taking MMF only or MMF after AZA tended to show lower cumulative relapse-free (p=0.117) and ESRD-free (p=0.059) rates during follow-up, compared to those in patients taking AZA only. However, they did not reach statistical significance. The numbers below are the number of patients followed at each period (0, 50, 100, 150 months). MMF, mycophenolate mofetil; AZA, azathioprine; ESRD, end-stage renal disease; CVA, cerebrovascular accident; CVD, cardiovascular disease.